Literature DB >> 11038298

Mechanisms of ischemic preconditioning in skeletal muscle.

L Gürke1, A Mattei, K Chaloupka, A Marx, P M Sutter, P Stierli, F Harder, M Heberer.   

Abstract

BACKGROUND: Ischemic preconditioning (IP) (one or more cycles each consisting of a short period of ischemia and a short period of reperfusion, before the sustained ischemia) reduces ischemia-related organ damage in heart and skeletal muscle but the underlying mechanisms are not clear. This study was intended to assess the possible involvement of K(ATP) channels and of adenosine receptors in IP of skeletal muscle in a rat model of skeletal muscle ischemia.
MATERIALS AND METHODS: Groups of 8-15 rats were given the following in vivo treatments: ischemia-reperfusion (I-R: 2.5 h tourniquet-induced ischemia of the right hindlimb, then 2 h reperfusion); IP (three cycles of 5 min ischemia, then 5 min reperfusion) before I-R; cromakalim and I-R; glibenclamide, cromakalim, and I-R; glibenclamide, IP, and I-R; [R]-N(6)-[1-methyl-2-phenylethyl]adenosine (R-PIA) and I-R; adenosine and I-R; and glibenclamide, IP, and I-R. Parameters of muscle function (postischemic maximal force, performance, contraction index, and force after 1 min of stimulation) were then assessed in vitro in the extensor digitorum longus muscle.
RESULTS: Pretreatment with either IP or the K(ATP) channel opener cromakalim significantly improved postischemic muscle function. The protective effect of cromakalim was not seen when the K(ATP) channel blocker glibenclamide was added. Glibenclamide, however, did not block IP-induced protection. Pretreatment with the adenosine A(1) receptor agonist 8-(p-sulfophenyl)-theophyllin (8-SPT) or with adenosine did not improve postischemic muscle function. The adenosine receptor agonist did not block IP-induced protection against ischemic damage.
CONCLUSIONS: The results show significant improvements in postischemic skeletal muscle function after IP or cromakalim pretreatment but they do not support a role for K(ATP) channels or for adenosine receptors in IP of skeletal muscle. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11038298     DOI: 10.1006/jsre.2000.5987

Source DB:  PubMed          Journal:  J Surg Res        ISSN: 0022-4804            Impact factor:   2.192


  6 in total

1.  Cell survival signalling in heart derived myofibroblasts induced by preconditioning and bradykinin: the role of p38 MAP kinase.

Authors:  Marie Cooper; Kirsti Ytrehus
Journal:  Mol Cell Biochem       Date:  2004-04       Impact factor: 3.396

2.  Administration of particulate oxygen generators improves skeletal muscle contractile function after ischemia-reperfusion injury in the rat hindlimb.

Authors:  Sarah E Dyer; J David Remer; Kelsey E Hannifin; Aishwarya Hombal; Joseph C Wenke; Thomas J Walters; George J Christ
Journal:  J Appl Physiol (1985)       Date:  2022-01-06

3.  500 ml of blood loss does not decrease non-invasive tissue oxygen saturation (StO2) as measured by near infrared spectroscopy - A hypothesis generating pilot study in healthy adult women.

Authors:  Victor Jeger; Stephan M Jakob; Stefano Fontana; Martin Wolf; Heinz Zimmermann; Aristomenis K Exadaktylos
Journal:  J Trauma Manag Outcomes       Date:  2010-05-13

4.  Effects of ischemic preconditioning of different intraoperative ischemic times of vascularized bone graft rabbit models.

Authors:  Ahmad Sukari Halim; Wan Syazli Rodzaia Wan Ahmad Kamal; Norizal Mohd Noor; Shafie Abdullah
Journal:  Arch Plast Surg       Date:  2013-11-08

5.  Enhanced Local Skeletal Muscle Oxidative Capacity and Microvascular Blood Flow Following 7-Day Ischemic Preconditioning in Healthy Humans.

Authors:  Owen Jeffries; Mark Waldron; John R Pattison; Stephen D Patterson
Journal:  Front Physiol       Date:  2018-05-09       Impact factor: 4.566

6.  Effect of Ischemic Preconditioning on Marathon-Induced Changes in Serum Exerkine Levels and Inflammation.

Authors:  Jan Mieszkowski; Błażej Stankiewicz; Andrzej Kochanowicz; Bartłomiej Niespodziński; Andżelika Borkowska; Jędrzej Antosiewicz
Journal:  Front Physiol       Date:  2020-10-21       Impact factor: 4.566

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.